Peptide sterility testing: reading a no-growth result

Read the method, sampled amount, recovery checks and incubation dates behind a peptide sterility result, and distinguish it from bioburden testing.

Substantially revised to focus on peptide identity, testing and documentation; related guides consolidated.

A reported no-growth result needs its method, sample and completed test period. This guide explains the questions to ask when a peptide or laboratory-water certificate includes a sterility row.

What a no-growth result describes

Culture-based sterility testing looks for growth under the specified test conditions. Sampling and recovery limitations matter: the result concerns the material tested under those conditions, rather than a direct observation of every unit in a lot.FDA sterility-testing context (opens in a new tab)

USP’s public recovery introduction explains why the method must be suitable for the product matrix. A material that prevents recovery can complicate interpretation, so ask whether the relevant suitability checks were completed. This guide does not establish which tests were performed on any unlisted product.USP — Validation of microbial recovery (opens in a new tab)

Distinguish sterility and bioburden

Different microbiological reporting questions
EntryReading task
No growthIdentify the culture method, tested amount, recovery and completed incubation
CFU resultPreserve the colony-forming-unit count and represented mass or volume
Bacterial endotoxin resultRead its separate assay and EU reporting basis
Chromatographic purityRead the chemical separation result separately
USP — Microbial enumeration tests (opens in a new tab)USP — Validation of microbial recovery (opens in a new tab)Bachem analytical guide (opens in a new tab)FDA endotoxin-testing guidance (opens in a new tab)

A CFU count concerns organisms recovered and counted under the enumeration method. Its denominator and recovery conditions are essential; it is not interchangeable with a no-growth conclusion from a different test.USP — Microbial enumeration tests (opens in a new tab)USP — Validation of microbial recovery (opens in a new tab)

Check the test period

USP’s public <1071> introduction describes a minimum 14-day incubation for the conventional growth-based <71> tests. A report using that label with a much shorter apparent timeline needs clarification of the complete dates and method. A rapid method must be identified rather than assumed.USP — Rapid microbial tests for sterile short-life products (opens in a new tab)

The supplied laboratory-water certificate records receipt on 4 September, analysis on 5–6 September and approval on 7 September 2026 alongside a USP <71> no-growth result. Those transcribed dates leave the timeline unresolved; the water-certificate guide records the question without inventing a correction.Water report (PDF) (opens in a new tab)USP — Rapid microbial tests for sterile short-life products (opens in a new tab)

Ask for the sampled amount, test start and finish dates, recovery evidence and any amended report. Keep the answer connected to the original sample and report version.FDA sterility-testing context (opens in a new tab)USP — Validation of microbial recovery (opens in a new tab)

Sources and further detail

  1. FDA — Aseptic-processing guidance (2004), sterility-testing section (opens in a new tab)

    Sampling and recovery limitations only; no product-specific compliance determination.

  2. USP — Validation of microbial recovery (opens in a new tab)

    Public introduction to <1227>. Product-specific recovery suitability; full chapter not reproduced.

  3. USP — Rapid microbial tests for sterile short-life products (opens in a new tab)

    2025 public introduction to <1071>, including the conventional <71> incubation-period distinction. No rapid method is assumed for a supplied report.

  4. USP — Microbial enumeration tests (opens in a new tab)

    Public <61> introduction defining the culture-based enumeration scope. Full current procedural requirements are not reproduced.

  5. Bachem — Quality control of amino acids and peptides (opens in a new tab)

    Sections on identity, purity and product content. Used for the distinction between chromatographic area and material content.

  6. FDA — Endotoxin-testing guidance, edition 2 (2026) (opens in a new tab)

    Assay terminology and sample-specific interpretation only.

  7. Supplied bacteriostatic water 3 mL certificate (opens in a new tab)

    MA-WFI-0047, revision 01; task TJK2ADP; lot WFI-47-ADP. TOC sample basis and sterility-test timing remain unresolved; see the article. The cited PDF was re-read on 3 October 2026 to check this transcription; its issuer and findings were not independently authenticated.

Revised from the existing source dossier on 3 October 2026. Supplied-report values are document transcriptions, not independent authentication or new measurements. Source notes identify the scope of each reference; this article has not undergone independent scientific peer review.

Novum Peptides

Research use only

Before you enter

Please confirm the following before browsing Novum Peptides.

Adults onlyYou must be 18 years or older to enter.

Laboratory research onlyOur products are not for human or veterinary use.

We’ll remember your confirmation on this browser where storage is available.

Novum Peptides · For laboratory research only